Literature DB >> 10982111

Improving value measurement in cost-effectiveness analysis.

P A Ubel1, E Nord, M Gold, P Menzel, J L Prades, J Richardson.   

Abstract

OBJECTIVE: Before cost-effectiveness analysis (CEA) can fulfill its promise as a tool to guide health care allocation decisions, the method of incorporating societal values into CEA may need to be improved.
DESIGN: The study design was a declarative exposition of potential fallacies in the theoretical underpinnings of CEA. Two values held by many people-preferences for giving priority to severely ill patients and preferences to avoid discrimination against people who have limited treatment potential because of disability or chronic illness-that are not currently incorporated into CEA are discussed.
CONCLUSIONS: Traditional CEA, through the measurement of quality-adjusted life years (QALYs), is constrained because of a "QALY trap." If, for example, saving the life of a person with paraplegia is equally valuable as saving the life of a person without paraplegia, then current QALY methods force us to conclude that curing paraplegia brings no benefit. Basing cost-effectiveness measurement on societal values rather than QALYs may allow us to better capture public rationing preferences, thereby escaping the QALY trap. CEA can accommodate a wider range of such societal values about fairness in its measurements by amending its methodology.

Entities:  

Mesh:

Year:  2000        PMID: 10982111     DOI: 10.1097/00005650-200009000-00003

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  12 in total

Review 1.  Resource allocation, social values and the QALY: a review of the debate and empirical evidence.

Authors:  David L B Schwappach
Journal:  Health Expect       Date:  2002-09       Impact factor: 3.377

Review 2.  [Public access defibrillation. Limited use by trained first responders and laymen].

Authors:  S Maisch; P Friederich; A E Goetz
Journal:  Anaesthesist       Date:  2006-12       Impact factor: 1.041

3.  Incorporating Equity Concerns in Cost-Effectiveness Analyses: A Systematic Literature Review.

Authors:  Thomas Ward; Ruben E Mujica-Mota; Anne E Spencer; Antonieta Medina-Lara
Journal:  Pharmacoeconomics       Date:  2021-10-29       Impact factor: 4.981

4.  Hidden costs: The ethics of cost-effectiveness analyses for health interventions in resource-limited settings.

Authors:  Sarah E Rutstein; Joan T Price; Nora E Rosenberg; Stuart M Rennie; Andrea K Biddle; William C Miller
Journal:  Glob Public Health       Date:  2016-05-04

5.  When are person tradeoffs valid?

Authors:  Jason N Doctor; John Miyamoto; Han Bleichrodt
Journal:  J Health Econ       Date:  2009-06-25       Impact factor: 3.883

6.  Obtaining utility estimates of the health value of commonly prescribed treatments for asthma and depression.

Authors:  Maria Orlando Edelen; M Audrey Burnam; Katherine E Watkins; José J Escarce; Haiden Huskamp; Howard H Goldman; Gary Rachelefsky
Journal:  Med Decis Making       Date:  2008-08-25       Impact factor: 2.583

7.  Trading people versus trading time: what is the difference?

Authors:  Laura J Damschroder; Todd R Roberts; Christine C Goldstein; Molly E Miklosovic; Peter A Ubel
Journal:  Popul Health Metr       Date:  2005-11-10

8.  Cost-effectiveness of tuberculosis evaluation and treatment of newly-arrived immigrants.

Authors:  Travis C Porco; Bryan Lewis; Elliot Marseille; Jennifer Grinsdale; Jennifer M Flood; Sarah E Royce
Journal:  BMC Public Health       Date:  2006-06-19       Impact factor: 3.295

9.  The equivalence of numbers: the social value of avoiding health decline: an experimental Web-based study.

Authors:  David L B Schwappach
Journal:  BMC Med Inform Decis Mak       Date:  2002-03-05       Impact factor: 2.796

10.  Multi-Stakeholder Decision Aid for Improved Prioritization of the Public Health Impact of Climate Sensitive Infectious Diseases.

Authors:  Valerie Hongoh; Pascal Michel; Pierre Gosselin; Karim Samoura; André Ravel; Céline Campagna; Hassane Djibrilla Cissé; Jean-Philippe Waaub
Journal:  Int J Environ Res Public Health       Date:  2016-04-12       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.